The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The mechanism of action of anti-CD47 antibodies & where these may fit in the MDS treatment landscape
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares some insights into the mechanism of action of anti-CD47 antibodies, highlighting the ongoing research on magrolimab in patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and the value of these agents in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
